venBio Partners

venBio Partners is a venture capital firm based in San Francisco, California, focusing on early-stage life sciences companies. Established in 2011, the firm has raised approximately $2 billion in capital commitments and has invested in over 40 companies, including Labrys Biologics, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Aurinia Pharmaceuticals, Apellis Pharmaceuticals, Checkmate Pharmaceuticals, Turning Point Therapeutics, Akero Therapeutics, Harmony Biosciences, Pharvaris, CinCor Pharma, and RayzeBio. venBio Partners primarily invests in therapeutics companies developing biopharmaceuticals to address unmet medical needs. The firm takes an active role with each portfolio company, providing strategic guidance on research, clinical, and business activities. venBio Partners seeks opportunities across all stages of clinical development, focusing on those providing meaningful clinical data and value inflection within three to five years. The firm's investment approach has led to nine FDA drug approvals over the past six years, with many more generating promising clinical efficacy and safety data. venBio Partners' portfolio companies have achieved significant value, demonstrating the firm's commitment to turning science into impactful medicine. The firm's managing partners include Richard Gaster, M.D., Ph.D., Corey Goodman, Ph.D., and Aaron Royston, M.D. In August 2024, venBio Partners closed its fifth life sciences venture capital fund, venBio Global Strategic Fund V, at approximately $528 million in capital commitments. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices, and funds-of-funds. The firm continues to focus on life science companies developing biopharmaceuticals to address unmet medical needs, maintaining its strategy of being highly selective in company building and providing strong support for portfolio companies in crossover rounds and at IPO. venBio Partners' commitment to its investment strategy and active involvement in portfolio companies has led to significant achievements in the life sciences sector, underscoring its role as a leading venture capital firm in the industry.

Focus on therapeutics companies developing biopharmaceuticals for unmet medical needs, Active involvement in portfolio companies, Opportunities across all stages of clinical development, Emphasis on meaningful clinical data and value inflection within three to five years